Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation Priority Review granted based on positive results from two Phase 3 trialsIf approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for the disease in more than a decadeRegulatory submissions are also under review in China and Europe Paris and Tarrytown, N.Y. February 23, 2024. The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental ...